Cancer Reporting Outcomes Questionnaire¶
On the Cancer Referral Overview Page, under Feedback Forms, you can complete the RoQ for a case by clicking the Review button.
Only the last version of the RoQ, for each case will be stored.
Under “Feedback Forms”, you can update and/or edit any Cancer RoQ by clicking on the Edit which will bring you to the Cancer Referral Feedback Form page.
Any field with a red asterisk * is a mandatory field that must be completed before the Feedback Form can be successfully saved.
Case Level Questions include the Analysis, Validation, and Reporting time for the case, which are reported in hours (e.g. 1, 2, 2.5, etc.).
In the Case Level Questions, the WGA outcomes include the option for a user to select either that Domain 1, and 2, or 1 and 2 and supplementary analysis were reviewed for that particular case.
Additional Comments is a free text field that will not be curated in any programmatic way. Therefore, add any enriched information that cannot be entered in either the Case Level Questions or the Variant Level Questions.
Case Level Questions¶
Analysis, validation and reporting time
Review Time
- Total time taken to review/collate evidence for variants (hours). Include all literature review time, consultation with relevant experts etc.
- Time taken to discuss case at MDT (hours).
- If the case is discussed at a 2nd MDT please enter time here (hours).
Validation Time
- Total time to design ALL validation assay(s) for case (hours). Only applicable if it is necessary to design a new assay to validate the variant.
- Technical Laboratory Validation. Total time for validation test wet work for all variants (hours).
- Analytical Laboratory Validation. Total time for analysis of validation results for all variants (hours).
Reporting Time
- Primary Reporting. Time taken to complete primary reporting stage (hours).
- Report Authorisation. Time taken to check and authorise report (hours).
- Report Distribution. Please enter, where possible/accessible how long it takes for the result to be conveyed to the patient. E.g. via letter from the clinician (days).
- Total time from result to report. The total time taken from when the analysis of the WGS results started to a report being received by the patient include any "waiting" time (days).
WGA Outcomes
- Which parts of the WGA were reviewed?
- Are there any variants in this report that would be potentially actionable for the tumour of this patient?
Additional comments
Free text field for entering any additional comments about the referral
Variant questions¶
Variant Level Questions - Potentially Actionable Variants
Questions to be answered for the potentially actionable variants in the referral
- Type of (potential) actionability:
- Predicts therapeutic response?
- Prognostic?
- Defines diagnosis group?
- Eligibility for trial?
- Other?
- How has/will this potentially actionable variant or entity been/be used?
- Has this variant or entity been tested by another method (either prior to or following receipt of this WGA)?
Recommendation for VUS
For Domain 1 and 2 Small Somatic VUS we recommend the user to respond as it follows:
Pathogenic germline cancer susceptibility variants¶
Variant Level Questions for pathogenic germline cancer susceptibility variants that are reported are shown below. A user can select more than one type of actionability in the checkboxes, but only one field is available for how the potentially actionable variant has been used, whether it has been tested by another method, and free text for validation assay type.
Variant Level Questions - Potentially Actionable Variants
Questions to be answered for the potentially actionable variants in the referral
- Type of (potential) actionability:
- Germline susceptibility?
- Predicts therapeutic response?
- Prognostic?
- Defines diagnosis group?
- Eligibility for trial?
- Other?
- How has/will this potentially actionable variant or entity been/be used?
- Has this variant or entity been tested by another method (either prior to or following receipt of this WGA)?
- Please enter validation essay type e.g. Pyrosequencing, NGS panel, COBAS, Sanger sequencing. If not applicable enter NA"
Other actionable variants or entities¶
This enables the user to add or remove user-edited and defined variants, mutational signatures, mutational burden, or any other entity
- Somatic Domain 3 small variant
- Germline Tier 3 small variant
- SV CNV
- Mutational Signatures
- Mutation Burden
- Other
Adding multiple entities
Currently, the questionnaire supports the addition of only one entity per type of variable. If you find the need to include multiple entities of the same type, we recommend adding them them within the same Free Text Field.
Another workaround to add more than one variant per type is to edit the completed RoQ. To do this, first you close the RoQ by adding only one variant per type in the 'Other actionable variants or entities' field. Once the RoQ is submitted, from the Portal, click again on the 'Edit' button and add another variant.
Alternatively, to add more than one variant per type, you can follow this workaround:
- Complete the RoQ by adding only one variant per type in the 'Other actionable variants or entities' field.
- After submitting the RoQ, navigate to the Portal and click on the 'Edit' button.
- Add an additional variant per type with the 'Other actionable variants or entities' field.
- Submit the RoQ again, and repeat as necessary.